Updated:18 Oct 2017 03:31:00 PM(IST)
|Bse Corporate Announcements||Back|
|Lupin launches Zaxine® in Canada|
|Lupin announced that its Canadian subsidiary, Lupin Pharma Canada has launched its first brand product Zaxine® under strategic licensing agreement with the North Carolina based GI specialty company, Salix Pharmaceuticals Inc. The agreement grants Lupin exclusive rights to promote, distribute and market Zaxine® in the Canada.
Zaxine® 550mg (rifaximin) is a long term antibiotic treatment for adults living with hepatic encephalopathy (HE), a complication of liver disease (cirrhosis).